We are monitoring the impact of COVID-19 on Lung Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 833
Share on
Share on

Global Lung Cancer Therapeutics Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Treatment Type & Region - Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 833
Pages: 180

Global Lung Cancer Therapeutics Market Size (2021 to 2026)

As per this report, the global lung cancer therapeutics market size is estimated to be worth USD 9.49 billion by 2026 and USD 6.86 billion in 2021, growing at a CAGR of 6.7% during the forecast period.

Lung cancer is the second most commonly detected and has the highest death rate of all cancers in both men and women. Cigarette smoking is the projecting cause of lung cancer and is a malignant tumor regarded as an uninhibited growth of cell tissues in the lung. Lung cancer declines the lung capability to deliver oxygen to the bloodstream. Some of the key indications of lung cancer comprise appetite loss, wheezing, weight loss, coughing, mucus, shortness of breath, and chest pain.

Increasing occurrences of lung cancer because of the mounting smoking population is one of the major factors driving the growth of the global lung cancer therapeutics market. Additionally, the introduction of superior-priced drugs and new advanced radiation therapies are the major drivers fuelling market growth. Novel and safer therapies could improve opportunities for the development of the global lung cancer therapeutics market.

Increasing investments in healthcare centers by the government and promoting quality treatment services is lucratively leveling up growth opportunities for the global lung cancer therapeutics market addition; the rise in the popularity of the treatment procedures through digital advertisements is lavishing the demand of the market. Also, growing disposable income in urban areas is merely prompting the growth rate of this market to the extent. Furthermore, the market is fuelled by ongoing research on developing new technologies in favor of the end-users. The emergence of the latest technology in radiation therapies is enhancing the growth rate of the market. The rise in the economy is well developed, and developing countries globally are significantly influencing the demand for the global lung cancer therapeutics market.

However, the devices require massive amounts for installation and maintenance to have accurate results, which are remained a challenging factor for the companies operating in the global lung cancer therapeutics market. In addition, at. A shortage of skilled persons inadequately managing the systems in real-time applications is slowly impeding the market's growth. Lack of standardization is one more attribute limiting the demand of the global lung cancer therapeutics market.

COVID-19 impact on the global lung cancer therapeutics market:

The COVID-19 outbreak has disrupted the mental and physical health conditions of the patients who have lung cancer. Moreover, lung cancer patients are at higher risk for this infectious disease. During the lockdown restrictions, the doctors treated only the emergency cases, whereas the remaining treatment or diagnosis for the cancer was postponed. With the slight relaxation by the government across the world, the demand for the market surges continuously. Maintaining social distancing and wearing masks are major regulations to prevent the spread of coronavirus. By following these measures, all the treatment services were resumed. As COVID 19 is attacking severely with lung cancer people, hospitals manage to take the utmost care. Therefore, the demand for the market is to get into a normal state by 2021. 

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Treatment Type and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, Agennix AG, AstraZeneca Plc and Sanofi-Aventi.

 

This research report on the global lung cancer therapeutics market has been segmented and sub-segmented based on treatment type and region.

Lung Cancer Therapeutics Market - By Treatment Type:

  • Chemotherapy
    • Cisplatin
    • Taxol
    • Navelbine
    • Camptosar
    • Alimta
  • Radiotherapy
    • External Beam
    • Internal Beam
    • Systemic
  • Other Drugs
    • Abraxane
    • Avastin
    • Crizotinib
    • Docetaxel
    • Gefitinib

By Treatment Type, Chemotherapy treatment type is growing at a faster rate from the past decade. The increasing success rate of chemotherapy due to the adoption of advanced technology is considered the primary factor for this segment to grow extensively. In addition, a rise in the demand for effective treatment procedures with fewer adverse effects is leveling up the growth of the global lung cancer therapeutics market. Increasing preference for early detection and diagnosis of diseases is also surging the growth rate of the markIn addition, stringentgent rules and regulations in approving new products regarding people’s safety are elevating the demand for the global lung cancer therapeutics market.

Lung Cancer Therapeutics Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, The lung cancer therapeutics market in the North America is leading globally. Lung cancer is the most common type of cancer in the U.S, and the majority of the population die of lung cancer every year. The market is majorly driven by the increasingly common and regular diagnostics of lung cancer and the rising acquisition of advanced lung cancer therapeutics. The increasing aging population in this region is another prime factor for the market to growth, lifestyle changes and smoking habits lead to a large pool of carcinoma lung populations responsible for the vast occurrence of lung cancer. The U.S is dominating the lung cancer therapeutics market in terms of income, followed by Canada. An evaluation of 228,150 adults, where 116,440 are men and 111,710 are women in the U.S, is diagnosed with lung cancer, as per the American Society of Clinical Oncology 2019. 

The lung cancer therapeutics market in Europe is leading next to the North America gobally. Lifestyle changes, quick reimbursement policies, growing cases of infections, increasing rates of early detection, and a rise in alertness among the people escalate the region's market growth over the analysis period. The UK is leading the market with a large population base being affected with lung cancer, an increase in the aging population, and augmenting frequent approvals for drug development. On the other hand, Germany is expected to have rapid and high growth in the lung cancer therapeutics market.

The lung cancer therapeutics market in Asia-Pacific countries such as India and China are the developing regions for the global lung cancer therapeutics market due to the high occurrence of this disease and growing healthcare alertness. The lung cancer therapeutics market of Asia-Pacific is expected to showcase profitable growth and is predicted to have fast growth. Factors like a vast population base drive the market, increasing knowledge among the people, medical needs, and government funds, particularly in developing economies like India and China.

The lung cancer therapeutics market in Latin America has got steady and fixed growth throughout the period. The governments of developed economies in Latin America are likely to bring awareness by organizing specific programs and campaigns regarding lung cancer. Mexico is dominating the lung cancer therapeutics market and is believed to retain its dominance over the analysis period. Argentina is predicted to be observed to have a massive growth in the upcoming years in the region.

The lung cancer therapeutics market Middle East & Africa is likely to have the least share during the forecast period. The factors like increasing approvals for alterations and improvements made in treatments propel the region's market growth. Africa is dominating the lung cancer therapeutics market due to an increase in the aged population and rising demand for the region's targeted therapies.

KEY MARKET PLAYERS:

Some of the notable participants dominating the global lung cancer therapeutics market profiled in this report are Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, Agennix AG, AstraZeneca Plc and Sanofi-Aventi.

Companies are implementing various strategies to increase their product portfolio and raise their geographical presence. New product expansion, contracts, associations, and procurements are some of the manufacturers' effective lung cancer therapeutics market approaches.

KEY HAPPENINGS IN THIS MARKET IN THE RECENT PAST:

  • AstraZeneca received marketing authorization approval from the National Medical Products Administration (NMPA) in September 2019 in China for Tagrisso, an EGFR tyrosine kinase inhibitor. This drug is used for patients with EGFR-mutated non-small cell lung cancer. The approval has provided the marketing and commercialization of drug exclusivity to Chinese firms, further expanding the business.
  • F. Hoffmann-La Roche Ltd received approval from the US FDA for Cobas EGFR Mutation Test v2 in August 2018. Cobas is a liquid biopsy diagnostic test in general used in combination with Irresa (gefitinib), an EGFR inhibitor for treating non-small cell lung cancer (NSCLC). It is the only FDA-approved diagnostic test for NSCLC. This test will provide useful and safer therapy for patients with NSCLC and expands the diagnostic business segment of F. Hoffmann-La Roche Ltd.
  • In March 2019, Adorx Therapeutics Limited announced that it had entered into long-term aims and interests of partnership with Johnson & Johnson Innovation LLC and Lung Cancer Initiative at Johnson & Johnson (LCI) of new novel lung cancer therapeutics. 
  • In June 2016, the American Society of Clinical Oncology (ASCO) had announced that a new antibody-drug conjugate had shown an early promise in the treatment of small-cell lung cancer.

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

5. Market Segmentation                                                              

                5.1 By Treatment Type                                 

                                5.1.1 Chemotherapy                     

                                                5.1.1.1 Cisplatin

                                                5.1.1.2 Taxol      

                                                5.1.1.3 Navelbine            

                                                5.1.1.4 Camptosar          

                                                5.1.1.5 Alimta   

                                5.1.2 Radiotherapy                         

                                                5.1.2.1 External Beam   

                                                5.1.2.2 Internal Beam    

                                                5.1.2.3 Systemic              

                                5.1.3 Other Drugs                            

                                                5.1.3.1 Abraxane             

                                                5.1.3.2 Avastin 

                                                5.1.3.3 Crizotinib             

                                                5.1.3.4 Docetaxel            

                                                5.1.3.5 Gefitinib               

6. Geographical Analysis                                                              

                6.1 North America                                          

                                6.1.1 Introduction                           

                                6.1.2 United States                         

                                6.1.3 Canada                     

                6.2 Europe                                         

                                6.2.1 Introduction                           

                                6.2.2 U.K                             

                                6.2.3 Spain                         

                                6.2.4 Germany                 

                                6.2.5 Italy                           

                                6.2.6 France                      

                6.3 Asia-Pacific                                 

                                6.3.1 Introduction                           

                                6.3.2 China                         

                                6.3.3 India                          

                                6.3.4 Japan                        

                                6.3.5 South Korea                           

                                6.3.6 Australia                  

                6.4 Latin America                                            

                                6.4.1 Introduction                           

                                6.4.2 Brazil                         

                                6.4.3 Mexico                     

                                6.4.4 Argentina                

                                6.4.5 Rest of Latin America                         

                6.5 Middle East & Africa                               

                                6.5.1 Introduction                           

                                6.5.2 Middle-East                            

                                6.5.3 Africa                        

7. Pipeline Product Analysis                                                       

                7.1 Overview                                                    

                7.2 Pipeline Development Landscape                                                    

                7.3 Molecular Targets in the Pipeline                                                     

                7.4 Clinical Trials                                             

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target                       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                                  

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.                               

8. Strategic Analysis                                                       

                8.1 PESTLE analysis                                         

                                8.1.1 Political                     

                                8.1.2 Economic                 

                                8.1.3 Social                         

                                8.1.4 Technological                         

                                8.1.5 Legal                          

                                8.1.6 Environmental                      

                8.2 Porter’s Five analysis                                              

                                8.2.1 Bargaining Power of Suppliers                        

                                8.2.2 Bargaining Power of Consumers                    

                                8.2.3 Threat of New Entrants                     

                                8.2.4 Threat of Substitute Products and Services               

                                8.2.5 Competitive Rivalry within the Industry                      

9. Market Leaders' Analysis                                                        

                9.1 BoehringerIngelheim GmbH                               

                                9.1.1 Overview                

                                9.1.2 Product Analysis                   

                                9.1.3 Strategic Evaluation and Operations                            

                                9.1.4 Financial analysis                  

                                9.1.5 Legal issues                            

                                9.1.6 Recent Developments                       

                                9.1.7 SWOT analysis                       

                                9.1.8 Analyst View                          

                9.2 Hoffman-La Roche                                  

                9.3 Pfizer Inc.                                    

                9.4 GlaxoSmitKline                                         

                9.5 Eli Lilly and Company                                             

                9.6 AstrazenecaPlc                                         

                9.7 Sanofi-Aventis                                          

                9.8 Agennix AG                                

10. Competitive Landscape                                                         

                10.1 Market share analysis                                          

                10.2 Merger and Acquisition Analysis                                     

                10.3 Agreements, collaborations and Joint Ventures                                       

                10.4 New Product Launches                                       

11. Expert Opinions                                                        

                11.1 Market Outlook                                     

                11.2 Investment Opportunities                                 

12. Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  • Global, regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identify the regions that are still untapped

  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis

  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment

  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

  1. Global Lung Cancer Therapeutics Market, By Region, From 2021 to 2026 (USD Million)

  2. Global Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  3. Global Chemotherapy Market, By Region, From 2021 to 2026 (USD Million)

  4. Global Radiotherapy Market, By Region, From 2021 to 2026 (USD Million)

  5. Global Other Lung Cancer Therapeutic Drugs Market, By Region, From 2021 to 2026 (USD Million)

  6. Global Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  7. Global Cisplatin Market, By Region, From 2021 to 2026 (USD Million)

  8. Global Taxol Market, By Region, From 2021 to 2026 (USD Million)

  9. Global Navelbine Market, By Region, From 2021 to 2026 (USD Million)

  10. Global Camptosar Market, By Region, From 2021 to 2026 (USD Million)

  11. Global Alimta Market, By Region, From 2021 to 2026 (USD Million)

  12. Global Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  13. Global External Beam Market, By Region, From 2021 to 2026 (USD Million)

  14. Global Internal Beam Market, By Region, From 2021 to 2026 (USD Million)

  15. Global Systemic Market, By Region, From 2021 to 2026 (USD Million)

  16. Global Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  17. Global Abraxane Market, By Region, From 2021 to 2026 (USD Million)

  18. Global Avastin Market, By Region, From 2021 to 2026 (USD Million)

  19. Global Crizotinib Market, By Region, From 2021 to 2026 (USD Million)

  20. Global Docetaxel Market, By Region, From 2021 to 2026 (USD Million)

  21. Global Gefitinib Market, By Region, From 2021 to 2026 (USD Million)

  22. North America Lung Cancer Therapeutics Market, By Region, From 2021 to 2026 (USD Million)

  23. North America Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  24. North America Chemotherapy Market, By Region, From 2021 to 2026 (USD Million)

  25. North America Radiotherapy Market, By Region, From 2021 to 2026 (USD Million)

  26. North America Other Lung Cancer Therapeutic Drugs Market, By Region, From 2021 to 2026 (USD Million)

  27. United States Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  28. Canada Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  29. North America Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  30. North America Cisplatin Market, By Region, From 2021 to 2026 (USD Million)

  31. North America Taxol Market, By Region, From 2021 to 2026 (USD Million)

  32. North America Navelbine Market, By Region, From 2021 to 2026 (USD Million)

  33. North America Camptosar Market, By Region, From 2021 to 2026 (USD Million)

  34. North America Alimta Market, By Region, From 2021 to 2026 (USD Million)

  35. United States Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  36. Canada Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  37. North America Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  38. North America External Beam Market, By Region, From 2021 to 2026 (USD Million)

  39. North America Internal Beam Market, By Region, From 2021 to 2026 (USD Million)

  40. North America Systemic Market, By Region, From 2021 to 2026 (USD Million)

  41. United States Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  42. Canada Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  43. North America Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  44. North America Abraxane Market, By Region, From 2021 to 2026 (USD Million)

  45. North America Avastin Market, By Region, From 2021 to 2026 (USD Million)

  46. North America Crizotinib Market, By Region, From 2021 to 2026 (USD Million)

  47. North America Docetaxel Market, By Region, From 2021 to 2026 (USD Million)

  48. North America Gefitinib Market, By Region, From 2021 to 2026 (USD Million)

  49. United States Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  50. Canada Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  51. Europe Lung Cancer Therapeutics Market, By Region, From 2021 to 2026 (USD Million)

  52. Europe Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  53. Europe Chemotherapy Market, By Region, From 2021 to 2026 (USD Million)

  54. Europe Radiotherapy Market, By Region, From 2021 to 2026 (USD Million)

  55. Europe Other Lung Cancer Therapeutic Drugs Market, By Region, From 2021 to 2026 (USD Million)

  56. U.K Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  57. Spain Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  58. Germany Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  59. Italy Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  60. France Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  61. Europe Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  62. Europe Cisplatin Market, By Region, From 2021 to 2026 (USD Million)

  63. Europe Taxol Market, By Region, From 2021 to 2026 (USD Million)

  64. Europe Navelbine Market, By Region, From 2021 to 2026 (USD Million)

  65. Europe Camptosar Market, By Region, From 2021 to 2026 (USD Million)

  66. Europe Alimta Market, By Region, From 2021 to 2026 (USD Million)

  67. U.K Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  68. Spain Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  69. Germany Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  70. Italy Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  71. France Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  72. Europe Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  73. Europe External Beam Market, By Region, From 2021 to 2026 (USD Million)

  74. Europe Internal Beam Market, By Region, From 2021 to 2026 (USD Million)

  75. Europe Systemic Market, By Region, From 2021 to 2026 (USD Million)

  76. U.K Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  77. Spain Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  78. Germany Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  79. Italy Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  80. France Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  81. Europe Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  82. Europe Abraxane Market, By Region, From 2021 to 2026 (USD Million)

  83. Europe Avastin Market, By Region, From 2021 to 2026 (USD Million)

  84. Europe Crizotinib Market, By Region, From 2021 to 2026 (USD Million)

  85. Europe Docetaxel Market, By Region, From 2021 to 2026 (USD Million)

  86. Europe Gefitinib Market, By Region, From 2021 to 2026 (USD Million)

  87. U.K Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  88. Spain Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  89. Germany Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  90. Italy Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  91. France Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  92. Asia-Pacific Lung Cancer Therapeutics Market, By Region, From 2021 to 2026 (USD Million)

  93. Asia-Pacific Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  94. Asia-Pacific Chemotherapy Market, By Region, From 2021 to 2026 (USD Million)

  95. Asia-Pacific Radiotherapy Market, By Region, From 2021 to 2026 (USD Million)

  96. Asia-Pacific Other Lung Cancer Therapeutic Drugs Market, By Region, From 2021 to 2026 (USD Million)

  97. China Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  98. India Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  99. Japan Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  100. South Korea Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  101. Australia Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  102. Asia-Pacific Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  103. Asia-Pacific Cisplatin Market, By Region, From 2021 to 2026 (USD Million)

  104. Asia-Pacific Taxol Market, By Region, From 2021 to 2026 (USD Million)

  105. Asia-Pacific Navelbine Market, By Region, From 2021 to 2026 (USD Million)

  106. Asia-Pacific Camptosar Market, By Region, From 2021 to 2026 (USD Million)

  107. Asia-Pacific Alimta Market, By Region, From 2021 to 2026 (USD Million)

  108. China Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  109. India Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  110. Japan Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  111. South Korea Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  112. Australia Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  113. Asia-Pacific Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  114. Asia-Pacific External Beam Market, By Region, From 2021 to 2026 (USD Million)

  115. Asia-Pacific Internal Beam Market, By Region, From 2021 to 2026 (USD Million)

  116. Asia-Pacific Systemic Market, By Region, From 2021 to 2026 (USD Million)

  117. China Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  118. India Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  119. Japan Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  120. South Korea Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  121. Australia Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  122. Asia-Pacific Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  123. Asia-Pacific Abraxane Market, By Region, From 2021 to 2026 (USD Million)

  124. Asia-Pacific Avastin Market, By Region, From 2021 to 2026 (USD Million)

  125. Asia-Pacific Crizotinib Market, By Region, From 2021 to 2026 (USD Million)

  126. Asia-Pacific Docetaxel Market, By Region, From 2021 to 2026 (USD Million)

  127. Asia-Pacific Gefitinib Market, By Region, From 2021 to 2026 (USD Million)

  128. China Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  129. India Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  130. Japan Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  131. South Korea Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  132. Australia Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  133. Latin America Lung Cancer Therapeutics Market, By Region, From 2021 to 2026 (USD Million)

  134. Latin America Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  135. Latin America Chemotherapy Market, By Region, From 2021 to 2026 (USD Million)

  136. Latin America Radiotherapy Market, By Region, From 2021 to 2026 (USD Million)

  137. Latin America Other Lung Cancer Therapeutic Drugs Market, By Region, From 2021 to 2026 (USD Million)

  138. Brazil Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  139. Argentina Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  140. Mexico Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  141. Latin America Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  142. Latin America Cisplatin Market, By Region, From 2021 to 2026 (USD Million)

  143. Latin America Taxol Market, By Region, From 2021 to 2026 (USD Million)

  144. Latin America Navelbine Market, By Region, From 2021 to 2026 (USD Million)

  145. Latin America Camptosar Market, By Region, From 2021 to 2026 (USD Million)

  146. Latin America Alimta Market, By Region, From 2021 to 2026 (USD Million)

  147. Brazil Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  148. Argentina Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  149. Mexico Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  150. Latin America Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  151. Latin America External Beam Market, By Region, From 2021 to 2026 (USD Million)

  152. Latin America Internal Beam Market, By Region, From 2021 to 2026 (USD Million)

  153. Latin America Systemic Market, By Region, From 2021 to 2026 (USD Million)

  154. Brazil Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  155. Argentina Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  156. Mexico Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  157. Latin America Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  158. Latin America Abraxane Market, By Region, From 2021 to 2026 (USD Million)

  159. Latin America Avastin Market, By Region, From 2021 to 2026 (USD Million)

  160. Latin America Crizotinib Market, By Region, From 2021 to 2026 (USD Million)

  161. Latin America Docetaxel Market, By Region, From 2021 to 2026 (USD Million)

  162. Latin America Gefitinib Market, By Region, From 2021 to 2026 (USD Million)

  163. Brazil Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  164. Argentina Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  165. Mexico Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  166. Middle East & Africa Lung Cancer Therapeutics Market, By Region, From 2021 to 2026 (USD Million)

  167. Middle East & Africa Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  168. Middle East & Africa Chemotherapy Market, By Region, From 2021 to 2026 (USD Million)

  169. Middle East & Africa Radiotherapy Market, By Region, From 2021 to 2026 (USD Million)

  170. Middle East & Africa Other Lung Cancer Therapeutic Drugs Market, By Region, From 2021 to 2026 (USD Million)

  171. Middle East Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  172. Africa Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Million)

  173. Middle East & Africa Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  174. Middle East & Africa Cisplatin Market, By Region, From 2021 to 2026 (USD Million)

  175. Middle East & Africa Taxol Market, By Region, From 2021 to 2026 (USD Million)

  176. Middle East & Africa Navelbine Market, By Region, From 2021 to 2026 (USD Million)

  177. Middle East & Africa Camptosar Market, By Region, From 2021 to 2026 (USD Million)

  178. Middle East & Africa Alimta Market, By Region, From 2021 to 2026 (USD Million)

  179. Middle East Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  180. Africa Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Million)

  181. Middle East & Africa Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  182. Middle East & Africa External Beam Market, By Region, From 2021 to 2026 (USD Million)

  183. Middle East & Africa Internal Beam Market, By Region, From 2021 to 2026 (USD Million)

  184. Middle East & Africa Systemic Market, By Region, From 2021 to 2026 (USD Million)

  185. Middle East Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  186. Africa Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Million)

  187. Middle East & Africa Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  188. Middle East & Africa Abraxane Market, By Region, From 2021 to 2026 (USD Million)

  189. Middle East & Africa Avastin Market, By Region, From 2021 to 2026 (USD Million)

  190. Middle East & Africa Crizotinib Market, By Region, From 2021 to 2026 (USD Million)

  191. Middle East & Africa Docetaxel Market, By Region, From 2021 to 2026 (USD Million)

  192. Middle East & Africa Gefitinib Market, By Region, From 2021 to 2026 (USD Million)

  193. Middle East Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

  194. Africa Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample